Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Breast Cancer: early-phase trial registry
74 of 140 indexed Metastatic Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #82 of 28,707 conditions by registered trial count.
140 US clinical trials · 74 currently recruiting · #82 of 28,707 conditions by registered trial count
Metastatic Breast Cancer: 140 US clinical trials tracked, 74 recruiting.
Metastatic Breast Cancer is the subject of 140 registered US clinical trials on ClinicalTrials.gov, 74 of them currently open to new participants. 11 are in Phase 3-4 (later-stage) and 99 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 12 of these trials.
Enrollment posture brief
Registry condition metastatic-breast-cancer
OPEN 74 | RECR 53% | LATE 11 | EARLY 99 | RANK #82 | SPON 12
Volume-matched condition peers
Nearest open-share peer: Solid Tumor (53% recruiting · 197 trials)
Metastatic Breast Cancer lists 74 open slots (53% of 140 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Breast Cancer is recruiting above its size-band peers.
74 of 140 indexed trials (52.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastatic Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 12 of 140 trials (8.6%). 93 distinct sponsors appear on at least one study for this condition label.
-
Typical Metastatic Breast Cancer enrolment sits around 71 participants.
Median target enrolment is 71 among the 140 trials that report a genuine target (sentinel values excluded). 78 of those (55.7%) plan for fewer than 100 participants.
-
Metastatic Breast Cancer research is mostly interventional.
128 interventional and 12 observational studies make up this index (91.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
140 total, page 1 of 3
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Olema Pharmaceuticals
NCT07085767
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Relay Therapeutics
NCT05216432
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Hoffmann-La Roche
NCT03424005
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
NCT06324357
Comprehensive Outcomes for After Cancer Health
Pack Health
NCT05349227
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Relay Therapeutics
NCT06982521
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Olema Pharmaceuticals
NCT06016738
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
American Society of Clinical Oncology
NCT06377852
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Sermonix Pharmaceuticals
NCT05696626
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Stemline Therapeutics
NCT05563220
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
BriaCell Therapeutics Corporation
NCT06072612
Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer
Massachusetts General Hospital
NCT06795529
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT06625775
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
BioNTech SE
NCT06827236
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Ana C Garrido-Castro, MD
NCT06533826
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeiGene
NCT06120283
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Kristina A. Fanucci
NCT07222215
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
NCT05894239
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Brigham and Women's Hospital
NCT04030507
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT06099769
The COMPASSION Study
Dana-Farber Cancer Institute
NCT06507930
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Olema Pharmaceuticals
NCT05508906
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Olema Pharmaceuticals
NCT06784193
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
Medical College of Wisconsin
NCT03824145
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
NCT06062498
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06157892
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Kathy Miller
NCT05846789
A Study of Surgery and Radiotherapy in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT07053085
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Puma Biotechnology
NCT06369285
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Memorial Sloan Kettering Cancer Center
NCT03808337
PRE-I-SPY Phase I/Ib Oncology Platform Program
QuantumLeap Healthcare Collaborative
NCT05868226
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
Merck Sharp & Dohme
NCT06428396
Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
UNC Lineberger Comprehensive Cancer Center
NCT06855654
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
BeOne Medicines
NCT06756932
Scalp Cooling in MBC
Dana-Farber Cancer Institute
NCT04986579
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Edgewood Oncology
NCT04872166
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
Mayo Clinic
NCT06388122
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
University of California, San Francisco
NCT06774027
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
Boundless Bio
NCT07408089
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma
NCT05573126
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
University of Utah
NCT07203378
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
Reshma L. Mahtani, D.O.
NCT06263543
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
Minerva Biotechnologies Corporation
NCT04020575
Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai
NCT06405828
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
Washington University School of Medicine
NCT05977036
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Sonya Reid
NCT05693766
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Phoenix Molecular Designs
NCT04115306
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
SynDevRx
NCT05455619
Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise
UNC Lineberger Comprehensive Cancer Center
NCT07313306
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT06110793
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 52 |
| Phase 3 | 10 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Breast Cancer page
140 registered trials, 74 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 74 Metastatic Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Metastatic Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Breast Cancer condition card totals 140 registered trials; most-linked intervention Fulvestrant; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.